MK-5204: An orally active β-1,3-glucan synthesis inhibitor-Reference-Cited by-同舟云学术

MK-5204: An orally active β-1,3-glucan synthesis inhibitor

Published:2020-09 Issue:17 Volume:30 Page:127357
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Apgar James M.^ORCID,Wilkening Robert R.,Parker Dann L.,Meng Dongfang,Wildonger Kenneth J.,Sperbeck Donald,Greenlee Mark L.,Balkovec James M.,Flattery Amy M.,Abruzzo George K.,Galgoci Andrew M.,Giacobbe Robert A.,Gill Charles J.,Hsu Ming-Jo,Liberator Paul,Misura Andrew S.,Motyl Mary,Kahn Jennifer Nielsen,Powles Maryann,Racine Fred,Dragovic Jasminka,Fan Weiming,Kirwan Robin,Lee Shu,Liu Hao,Mamai Ahmed,Nelson Kingsley,Peel Michael

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference28 articles.

1. Invasive Candidiasis

2. Fungal Infections

3. Invasive candidiasis: update on current pharmacotherapy options and future perspectives

4. Emerging drugs and vaccines for Candidemia

5. Therapy for fungal diseases: opportunities and priorities

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ten decadal advances in fungal biology leading towards human well-being;Fungal Diversity;2022-09

2. The Latest FDA-Approved Pharmaceuticals Containing Fragments of Tailor-Made Amino Acids and Fluorine;Pharmaceuticals;2022-08-14

3. Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor;Bioorganic & Medicinal Chemistry Letters;2021-01

4. Synthesis of MK-5204;Synfacts;2020-11-17